NIH Awards Drop 74 Percent as Funding Bottleneck Chokes Biomedical Research
April 5, 2026 · 2 min read
Jared Klein
The National Institutes of Health has issued 74 percent fewer competitive grants in fiscal year 2026 than the average for the same period across FY2021 through FY2024, according to a new analysis by the Association of American Universities. The monetary value of those awards is down 54 percent. For the nation's biomedical research enterprise, the numbers represent the worst grantmaking slowdown in modern NIH history.
Three Forces Behind the Collapse
The bottleneck stems from a convergence of disruptions. First, the White House Office of Management and Budget restricted NIH spending authority for nearly half the fiscal year, releasing the hold only on March 16. Second, a 43-day government shutdown in the fall consumed weeks of processing time. Third, a new requirement that every Notice of Funding Opportunity clear political appointees at NIH, HHS, and OMB has slowed the pipeline to a trickle — just 14 NOFOs published through mid-March, compared with 756 across all of 2024.
The agency has also lost over 4,000 employees, roughly 20 percent of its workforce, further eroding its capacity to review and issue awards. NIH Director Jay Bhattacharya has stated his "job is to make sure every single dollar goes out," but the pace suggests billions in congressionally appropriated funds remain unspent.
Early-Career Scientists Bear the Brunt
The damage is concentrated among researchers who can least absorb it. Success rates for early-stage investigators seeking their first R01-equivalent grant plummeted from 29.8 percent in FY2023 to 18.5 percent in FY2025, with FY2026 tracking worse. At the National Cancer Institute, which adopted the administration's multiyear forward-funding policy early, success rates have cratered from one in 10 to one in 25.
Overall, only 17 percent of research-grant applicants received an NIH award in FY2025 — the lowest success rate in 30 years. The multiyear funding policy alone is projected to eliminate roughly 970 competing grants in FY2026.
What Biomedical Grant Seekers Should Do Now
Researchers should not wait for the funding environment to stabilize. Diversify submissions across multiple NIH institutes, consider R21 exploratory grants alongside R01 applications, and explore parallel opportunities at NSF, DOD, and private foundations. Track NOFO releases weekly — when the backlog breaks, agencies will likely compress review timelines.
For deeper strategy on navigating the NIH funding crisis, grant seekers can find analysis and planning tools on grantedai.com.